GKOS stock forecast, quote, news & analysis
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases... Show more
Why Glaukos (GKOS) Stock Is Down -14% in the Last 30 Days
Key Takeaways
- Glaukos (GKOS) fell about 14% over the last 30 days, from a closing price of $179.87 on August 28, 2026, to $154.43 on September 25, 2026.
- The decline is largely profit-taking after the stock reached a 52-week high of $191.62 in August, rather than a deterioration in underlying business fundamentals.
- Proposed Medicare local coverage determinations (LCDs) for the company's iDose TR glaucoma implant remain a central reimbursement overhang.
- Despite the pullback, the shares remain roughly 7% higher over the trailing three months, reflecting the strong rally that followed second-quarter results.
- Fundamentals stayed robust: second-quarter revenue rose 50% year over year, and full-year 2026 revenue guidance was raised to $680–$700 million.
Glaukos (GKOS) Company Overview and Market Position
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases. Its core franchises include the iStent family of micro-invasive glaucoma surgery (MIGS) devices and iDose TR, a long-duration intracameral implant that delivers continuous glaucoma drug therapy inside the eye. The company is also building a corneal health platform around Epioxa, a corneal cross-linking therapy for keratoconus, and maintains a pipeline that includes iDose TREX, iDose TRIO, an iLink keratoconus screening device, and the retinal candidate GLK-401. Investors follow the stock for its leadership in interventional glaucoma and its attempt to shift glaucoma care toward earlier, procedure-based treatment.
Glaukos (GKOS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, GKOS declined from $179.87 to $154.43, a drop of approximately 14%. The slide began near the stock's 52-week high of $191.62, reached in mid-August, and unfolded through most of September as buyers stepped back after a strong run.
The quarterly picture is more mixed. In late June, the shares traded near $144. They then surged roughly a third to the August peak on the back of better-than-expected earnings before giving back much of that gain. As a result, the stock is still about 7% higher than it was three months earlier, even though the short-term trend has turned negative.
What Drove GKOS Stock Price in the Last 30 Days
The 30-day pullback appears driven primarily by valuation and sentiment rather than weakening operating results. After the stock hit $191.62, profit-taking accelerated, and a portion of the post-earnings rally was unwound as the shares moved back toward the broader analyst consensus target.
A key overhang has been reimbursement risk. Five of the seven Medicare Administrative Contractors issued proposed local coverage determinations for iDose TR, and the draft language raised concerns about restrictive step-edit criteria that could limit patient access and physician flexibility. Although management has expressed confidence that final determinations could be more favorable, the uncertainty has weighed on the shares.
Other factors added to the pressure. Insiders sold roughly $67 million of stock over the prior 12 months with no disclosed purchases, a signal some investors interpreted cautiously. The Epioxa launch, while progressing, remained early-stage with reimbursement and claims-processing friction. Finally, management itself cautioned that the third quarter is seasonally weaker for ophthalmology procedures, tempering near-term expectations after an exceptionally strong second quarter.
What Drove GKOS Stock Performance Over the Last Quarter
The quarter's dominant event was Glaukos' second-quarter earnings report, released July 29, 2026. The company posted record revenue of $185.6 million, up 50% year over year, driven by roughly $74 million in iDose TR sales. U.S. glaucoma revenue rose 64%, and corneal health revenue climbed 48% as Epioxa contributed about $11 million in its first full commercial quarter. Management raised full-year 2026 revenue guidance to $680–$700 million, up from $620–$635 million.
That momentum carried the stock to its 52-week high, but the rally also priced in considerable optimism. As the proposed iDose TR coverage determinations emerged and profit-taking set in, the shares experienced multiple compression, retreating despite the strong underlying growth story. The quarter thus illustrates a sharp run-up followed by a correction in a high-multiple, still-unprofitable growth name.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. Tickeron offers hundreds of bots that trade thousands of tickers, but only the top-performing and most relevant strategies appear in this section, helping traders filter through the noise. These bots vary widely in trading style, holding timeframe, and performance metrics, so investors can review them by their own criteria rather than adopting a one-size-fits-all approach. The page provides a useful starting point for anyone interested in systematic, data-driven trading ideas alongside their own research. Exploring the section can help identify strategies that align with individual risk preferences and objectives.
GKOS Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape the stock's near-term direction. First, investors will monitor the final iDose TR local coverage determinations from Medicare Administrative Contractors, which could clarify the reimbursement path for the company's largest growth driver. Second, the next quarterly earnings report will test whether iDose TR adoption and Epioxa's ramp can sustain momentum past a seasonally softer third quarter.
Further out, pipeline milestones matter, including the iDose TREX Phase IIb/III program, the iDose TRIO regulatory timeline, and the planned launch of the iLink keratoconus screening device. Macroeconomic conditions and interest-rate expectations also remain relevant, given the stock's elevated price-to-sales multiple and its reliance on future growth. Investors should weigh these catalysts against ongoing reimbursement, competitive, and execution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GKOS's RSI Indicator stays in oversold zone for 2 days
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 250 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
GKOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GKOS as a result. In 70 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for GKOS turned negative on August 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In 38 of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
GKOS moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GKOS crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for GKOS entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.351) is normal, around the industry mean (10.865). P/E Ratio (154.270) is within average values for comparable stocks, (98.603). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.050). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (39.828).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an ophthalmic medical device company
Industry MedicalNursingServices